Advertisement

Life-Sciences-Europe.com
The European Life Sciences Web Portal
This is a free web portal for the life sciences in Europe and Israel... » read more
- AI Alliance Launches to Advance Open, Safe, Responsible AI (2023-12-05)
IBM and Meta Launch the AI Alliance in collaboration with over 50 Founding Members and Collaborators globally including AMD, Anyscale, CERN, Cerebras, Cleveland Clinic, Cornell University, Dartmouth, Dell Technologies, EPFL, ETH, Hugging Face, Imperial College Lond... - IBA: Research Collaboration with U Kansas Medical Center (2023-12-05)
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announced today a research collaboration agreement with the University of Kansa... - Sofinnova Unveils AI Life Sciences Investment Platform (2023-12-05)
Combination of real time scientific databases with proprietary data will enable venture capital firm to enhance deal origination and portfolio growth through data-driven insights and strengthened entrepreneurial partnerships Sofinnova Partners (“Sofinnova"), a... - Eligo Bioscience Raises $30m Series B Led by Sanofi Ventures (2023-12-05)
> Financing led by Sanofi Ventures with participation from new investor Bpifrance (through its InnoBio 2 fund), and existing investors Khosla Ventures and Seventure Partners > Funding expected to generate proof of concept clinical data in patients Eligo Bio... - Aqemia: Multi-year, up to $140m Collaboration with Sanofi (2023-12-05)
This collaboration aims at accelerating the discovery of small molecules across various therapeutic areas, leveraging its unique Deep Physics platform combined with Generative AI. AQEMIA to receive up to a total of $140M in upfront and milestones across all program... - Roche to Acquire Carmot Therapeutics for up to $3.1b (2023-12-04)
> Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets > Lead asset CT-388 is a Phase-2 ready du... - Merck Licenses Pimicotinib from Abbisko [Not for US, et al.] (2023-12-04)
> Pimicotinib (ABSK021) is currently in a global Phase III study in tenosynovial giant cell tumor (TGCT) > Merck to receive an exclusive commercial license in mainland China, Hong Kong, Macau and Taiwan with option for rest of world > Pimicotinib has been gra... - Refeyn Launches KaritroMP Macro Mass Photometer (2023-11-30)
New macro mass photometer can assess the stability, quality, and purity of adenovirus and lentivirus vectors in just minutes Refeyn, a leader in mass photometry technology, announces the launch of its macro mass photometry platform, KaritroMP. This new benchto... - AAX Biotech & Oblique Tx Partner for Antibody Development (2023-11-28)
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is collaborating with Oblique Therapeutics, a biotech company developing new antibody medicines for severe diseases. This strategic collaboration will lever... - Boehringer & IBM: AI-based Antibody Drug Discovery (2023-11-28)
Today, Boehringer Ingelheim and IBM (NYSE: IBM) announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. “We are very excited to collabora...
Life-Sciences-Europe.com is your doorway to the European life sciences!
[LSE] provides free, up-to-date and structured access to
– News
– Products
– Persons
– Organisations
– Financings
– Collaborations
in Europe and Israel.
Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSE] is 100% Made in Germany!
» Start here with the latest News!Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top